PROCEPT BioRobotics (PRCT) TD Cowen 46th Annual Health Care Conference summary
Event summary combining transcript, slides, and related documents.
TD Cowen 46th Annual Health Care Conference summary
2 Mar, 2026Strategic initiatives and organizational changes
Implemented a new launch team structure, reallocating tenured staff and establishing regional leadership to improve system launches and utilization efficiency.
Launch team model aims to halve the time from purchase order to first 10 cases, with a goal for over half of new systems in 2024 to launch under this model.
Commercial restructuring separates launch and utilization teams, focusing the latter solely on same-store sales growth.
Incentive plans simplified to reward productivity, not behaviors, driving higher accountability and performance.
Organizational changes rolled out in January, with strong internal enthusiasm and stable attrition rates.
Inventory management and sales dynamics
Achieved near 1-to-1 handpiece inventory to procedure volume ratio, eliminating prior overstocking driven by end-of-quarter incentives.
Inventory equilibrium reached, with ongoing monitoring and adjustments as 200+ new systems are placed in 2024.
Discontinued volume-based discounts, returning customers to contracted prices without renegotiation.
Inventory levels now reflect natural usage patterns, supporting guidance and reducing revenue downside risk.
Capital strategy and forward-looking guidance
System placements for 2026 modeled to remain flat versus 2025, with pricing stable or slightly up.
Initiating a replacement strategy for legacy systems, offering trade-in credits to upgrade to HYDROS, with a larger focus expected in 2027–2028.
Exploring operational leases to expand access, with pilots planned for 2024 and broader rollout in future years.
2026 is positioned as a build year to develop capabilities for future replacement and leasing strategies.
Latest events from PROCEPT BioRobotics
- Q1 revenue up 20% to $83.1M, gross margin 65%, with strong U.S. and international growth.PRCT
Q1 202629 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay, with strong governance focus.PRCT
Proxy filing23 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and approve executive pay on June 9, 2026.PRCT
Proxy filing23 Apr 2026 - Strong growth, margin expansion, and innovation drive leadership in BPH and new cancer markets.PRCT
Investor Day 202626 Feb 2026 - Q4 saw record procedures and 12% revenue growth, with 2026 guidance targeting 27%–33% growth.PRCT
Q4 202526 Feb 2026 - Improved visibility, rising utilization, and new clinical studies drive strong growth and margin expansion.PRCT
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 revenue up 61% to $53.4M, gross margin at 59%, FY24 guidance raised to $217M.PRCT
Q2 20242 Feb 2026 - FDA clears next-gen AI robotic system, reaffirming 2024 guidance and enabling broad US rollout.PRCT
Status Update1 Feb 2026 - Strong clinical results and expanding adoption drive growth, with new cancer studies underway.PRCT
The 44th Annual William Blair Growth Stock Conference31 Jan 2026